News

Abcourt Mines Secures Financing for Sleeping Giant Mine Revival

Abcourt Mines Secures Financing for Sleeping Giant Mine Revival

Abcourt Mines Secures Financing for Sleeping Giant Mine Revival

Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB: ABMBF) has successfully secured debt financing amounting to US$8 million aimed at reigniting operations at its Sleeping Giant mine and mill. This significant step underscores the company’s commitment to rejuvenate its mining assets and execute its development strategy.

Debt Financing Details and Terms

On April 9, the Corporation inked a non-binding term sheet with Nebari Natural Resources Credit Fund II, LP, which outlines a secured financing facility of US$8 million (around C$11 million). This financing will incur interest at the Secured Overnight Financing Rate (SOFR) plus 12% and is structured over a 36-month term. Importantly, this financing is contingent on raising an additional US$6 million, which could include equity or subordinated debt, and will be subject to rigorous due diligence and final agreement execution.

Capital Utilization and Management Insights

Pascal Hamelin, President and CEO of Abcourt, expressed enthusiasm regarding the financing, highlighting, “This Financing Facility, coupled with equity funding, will provide the necessary capital to restart the Sleeping Giant mine and mill in line with our internal mine plan.” With the completion of these financings, alongside existing cash reserves, the corporation anticipates a solid position to rejuvenate the operation while also addressing working capital and corporate needs.

Strengthening Shareholder Value

Abcourt has worked diligently with partners to secure the necessary funding, aiming to meet the anticipated capital expenses outlined in their comprehensive internal plan. The financial strategies implemented are designed not only to initiate operations at Sleeping Giant but also to enhance the potential returns for shareholders.

Expansion of Equity Financing

The corporation has also expanded its previously reported non-brokered private placement offering, now comprising the sale of:

  • Up to 170,000,000 units priced at C$0.05 each;
  • Up to 141,666,667 common shares qualifying as “flow-through shares” at C$0.06 each for expected gross proceeds up to C$8,500,000, with C$1,668,040 raised already.

Each unit includes one common share and a warrant, allowing the purchase of an additional common share at C$0.08 for a term of 36 months post-closing. If the trading price of the common shares surpasses C$0.12 for 20 consecutive days within a specified timeframe, the company may accelerate the expiry of the warrants.

Regulatory Considerations

The securities associated with the private placement will remain subject to a restricted period ending four months plus a day after issuance. The offering has not been registered under U.S. Securities laws, meaning it cannot be offered or sold within the United States or to U.S. persons without registration or exemption.

Strategic Goals for the Sleeping Giant Mine

The funds raised will be allocated toward restarting the Sleeping Giant mine and mill, repaying outstanding payables, and fulfilling general corporate commitments. Closing for both the Financing Facility and Private Placement is expected around May 30, and these are contingent on regulatory approvals, including from the TSX Venture Exchange.

About Abcourt Mines Inc.

Abcourt Mines Inc. is an exploration company strategically positioned in northwestern Québec, focusing on the development of its Sleeping Giant mine and mill, alongside other assets such as the Flordin property. The corporation aims to advance exploration and maximize the potential of its holdings, enhancing shareholder value through prudent management.

Frequently Asked Questions

What is the purpose of the financing secured by Abcourt Mines?

The financing is aimed at restarting the Sleeping Giant mine and mill, ensuring operational capital and addressing corporate requirements.

Who are the partners involved in the financing?

Abcourt has engaged Nebari Natural Resources Credit Fund II, LP to secure the debt financing required for their operational goals.

What are the terms of the debt financing?

The financing facility is for US$8 million at an interest rate of SOFR plus 12%, with a term of 36 months.

How will the equity financing be utilized?

The proceeds from the equity financing will support the restart of the Sleeping Giant mine and cover working capital and other general corporate needs.

When is the expected closing date for these financings?

The financings are anticipated to close on or around May 30, pending necessary regulatory approvals.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Paulex Bio's PAL-119 Trials: A New Diabetes Frontier

Updated Category News Views 80

Chasing the Holy Grail in Diabetes Treatment The pursuit of a true remedy for diabetes is almost like hunting for the mythical beast—a challenge that's left plenty of contenders biting the dust over the years. Yet, here's Paulex Bio jumping right into the fray with their groundbreaking PAL-119. They're not just peddling another temporary fix like most on the market;...

Continue Reading
PRG Projects' London Studio Elevates Live Entertainment

Updated Category News Views 172

A New Stage for Creativity in London When the curtain rises on a fresh idea, it's often the unknowns that make or break a production. Now, with PRG Projects unveiling their spanking new Project Studio in London, the tech and creative worlds might just bridge their gap tighter than a stage curtain before showtime. London Welcomes PRG's Innovative Hub This isn't just...

Continue Reading
TriMas Streamlines Portfolio with Rapak Sale

Updated Category News Views 48

TriMas Sheds Rapak: A Strategic Move Here's a twist worth dissecting: TriMas Corporation (NASDAQ: TRS) has offloaded its subsidiary Rapak, LLC to the German industrial packaging giant, Ringmetall SE. This isn't just a business shuffle—it's a calculated pivot with eyes on sharpening the core business blade. As they announced from Bloomfield Hills, Michigan, this move...

Continue Reading
i-80 Gold's Q3 2026: Production Plans Unveiled

Updated Category News Views 31

Gold Miners on the Move: Eye on i-80 Wake up and smell the gold, folks. i-80 Gold is ramping up to increase its yearly gold production targets, aiming for a hefty 150,000 to 200,000 ounces by 2028. Now, if you’ve been around the block like me, you know these are the kind of numbers that get investors either shifting in their chairs or springing to their feet. A Brief...

Continue Reading
RD Technologies Ramps Up Cross-Border Payments

Updated Category News Views 185

RD Technologies: Revving Up the Payment Game RD Technologies is at it again, jazzing up its game in the cross-border payments realm. One can almost smell the digits doing a tango across continents—particularly as Hong Kong's financial warriors set their sights on beefing up trade between Africa and Asia. New Alliances in the Payment Arena Here's a roadmap: Connect the...

Continue Reading
Ascletis Showcases Bold Moves in Obesity Drug Arena

Updated Category News Views 163

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Continue Reading
Lincoln Avenue's Bold New Move: Affordable Senior Living

Updated Category News Views 33

A New Senior Housing Era Begins in Channahon If there's one thing the affordable housing game loves, it's the mix of ambition and grit—both of which Lincoln Avenue Communities (LAC) brings to the table with The Talia. This latest project in Channahon, Illinois, marks their fourth groundbreaking in the state, cementing LAC's place as a key player in providing quality...

Continue Reading
Kim Dunbar Sheds Light on Online Personalized Learning

Updated Category News Views 11

Picture a classroom without walls, the teacher always available, and students moving at their own pace. Sounds utopian, right? Well, Virtual Public School Expert Kim Dunbar is making sense of this approach at SC Whitmore School in Columbia, South Carolina, as she explains how this works in an online high school. Mastery-Based Learning: Beyond the Conventional Rigid...

Continue Reading
Neurocrine Biosciences Hits $1 Billion Mark in Q3 2026

Updated Category News Views 23

Neurocrine's Triple-Digit Surge Neurocrine Biosciences is on a tear, pushing its revenue up to a jaw-dropping $1.1 billion in Q3 2026—a hefty 41% leap from the previous year. Frankly, you can't ignore those numbers. INGREZZA, which is practically becoming a cash cow, did $801 million alone, rising 17% year over year. This rides the wave of prescription surges and solid...

Continue Reading
Dr. Huang's Honorary Degree Caps Global Impact Journey

Updated Category News Views 41

Recognition from Alma Mater Puts a Bow on a Storied Career When someone ventures out into the world and leaves a mark across continents, it’s a remarkable feat. It’s even more heartening when the place that helped shape them gets to extend a nod of recognition. Dr. Charles Huang, the mastermind behind Pasaca Capital, just unwound a new layer to his multicolored life...

Continue Reading
/neurocrine-biosciences-hits-1-billion-mark-in-q3-2026-540185-/" title="Neurocrine Biosciences Hits $1 Billion Mark in Q3 2026 - Continue Reading" aria-label="Continue reading: Neurocrine Biosciences Hits $1 Billion Mark in Q3 2026"> Continue Reading